Vectibix clinical trials (correction)
Amgen said it is continuing to study Vectibix (panitumumab), which failed to show survival benefits in a Phase IIIb trial, as a single biologic combined with chemotherapy in two Phase III trials in the first-and second-line of metastatic colorectal cancer. A previous article suggests that Vectibix failed to show survival benefits in a Phase IV commitment (1"The Pink Sheet" Aug. 20, 2007, p. 16). Phase IV commitments for Vectibix are progressing well, notably the registrational Phase III trial in the second-line of metastatic colorectal cancer, Amgen says...
You may also be interested in...
FDA is moving towards potentially withdrawing, for the first time, a drug brought to market under the Subpart H accelerated approval mechanism
US FDA not planning an advisory committee for Pfizer/BioNTech’s request for authorization in 12-15-year olds at this time, but CDC’s ACIP is likely to weigh how to balance timing of COVID vaccination with administration of other immunizations generally recommended for adolescents.
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.